Ieq Capital LLC Buys Shares of 13,757 TG Therapeutics, Inc. $TGTX

Ieq Capital LLC purchased a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 13,757 shares of the biopharmaceutical company’s stock, valued at approximately $756,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Danske Bank A S acquired a new stake in TG Therapeutics during the 3rd quarter worth approximately $25,000. EverSource Wealth Advisors LLC grew its holdings in TG Therapeutics by 51.9% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 365 shares during the last quarter. Hantz Financial Services Inc. increased its position in TG Therapeutics by 82.7% in the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 560 shares during the period. Truvestments Capital LLC raised its stake in shares of TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. bought a new position in shares of TG Therapeutics during the fourth quarter valued at $52,000. 58.58% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on TGTX shares. Jefferies Financial Group reissued a “buy” rating and issued a $83.00 price objective on shares of TG Therapeutics in a research note on Monday, June 22nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. HC Wainwright reissued a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a research note on Tuesday, August 4th. Finally, Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $63.00.

TG Therapeutics Trading Up 1.3%

TGTX opened at $55.72 on Friday. TG Therapeutics, Inc. has a twelve month low of $26.76 and a twelve month high of $59.30. The company has a quick ratio of 3.72, a current ratio of 4.27 and a debt-to-equity ratio of 1.23. The company has a fifty day moving average of $53.36 and a 200-day moving average of $41.74. The stock has a market cap of $8.53 billion, a PE ratio of 20.34, a price-to-earnings-growth ratio of 2.36 and a beta of 1.62.

TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The firm had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.TG Therapeutics’s quarterly revenue was up 70.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.17 EPS. On average, sell-side analysts predict that TG Therapeutics, Inc. will post 0.92 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small?molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.